Literature DB >> 8257227

Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure.

R M Roumen1, T Hendriks, J van der Ven-Jongekrijg, G A Nieuwenhuijzen, R W Sauerwein, J W van der Meer, R J Goris.   

Abstract

OBJECTIVE: This study investigates the course of serum cytokine levels in patients with multiple trauma, patients with a ruptured abdominal aortic aneurysm (AAA), and patients undergoing elective AAA repair and the relationship of these cytokines to the development of adult respiratory distress syndrome (ARDS) and multiple organ failure (MOF). SUMMARY BACKGROUND DATA: Severe tissue trauma, hemorrhagic shock, and ischemia-reperfusion injury are pathophysiologic mechanisms that may result in an excessive uncontrolled activation of inflammatory cells and mediators. This inflammatory response is thought to play a key role in the development of (remote) cell and organ dysfunction, which is the basis of ARDS and MOF.
METHODS: The study concerns 28 patients with multiple trauma, 20 patients admitted in shock because of a ruptured AAA, and 18 patients undergoing elective AAA repair. Arterial blood was serially sampled from admission (or at the start of elective operation) to day 13 in the intensive care unit, and the serum concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta, and IL-6 were determined.
RESULTS: Twenty-two patients died, 15 within 48 hours and 7 after several weeks, as a result of ARDS/MOF. At hospital admission and after 6 hours, these nonsurvivors had significantly higher plasma TNF-alpha and IL-1 beta levels than did the survivors. At the same measuring points, TNF-alpha and IL-1 beta were significantly more elevated in patients with ruptured AAA than in traumatized patients. However, IL-6 was significantly higher in the traumatized patients. In 10 patients, ARDS/MOF developed, and 41 had an uncomplicated course in this respect. Those with ARDS/MOF exhibited significantly different cytokine patterns in the early postinjury phase. TNF-alpha and IL-1 beta levels were higher mainly on the first day of admission; IL-6 concentrations were significantly elevated in patients with ARDS/MOF from the second day onward. The latter cytokine showed a good correlation with the daily MOF score during the whole 2-week observation period.
CONCLUSIONS: In the early postinjury phase, higher concentrations of these cytokines are associated, not only with an increased mortality rate, but also with an increased risk for subsequent ARDS and MOF. These data therefore support the concept that these syndromes are caused by an overwhelming autodestructive inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257227      PMCID: PMC1243073          DOI: 10.1097/00000658-199312000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  33 in total

1.  Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma.

Authors:  F A Moore; E E Moore; R Poggetti; O J McAnena; V M Peterson; C M Abernathy; P E Parsons
Journal:  J Trauma       Date:  1991-05

2.  Acute release of cytokines is proportional to tissue injury induced by surgical trauma and shock in rats.

Authors:  H Bitterman; A Kinarty; H Lazarovich; N Lahat
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

3.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

4.  Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury.

Authors:  M G Caty; K S Guice; K T Oldham; D G Remick; S I Kunkel
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

5.  Respiratory burst capability of polymorphonuclear neutrophils and TNF-alpha serum levels in relationship to the development of septic syndrome in critically ill patients.

Authors:  F Trautinger; A F Hammerle; G Pöschl; M Micksche
Journal:  J Leukoc Biol       Date:  1991-05       Impact factor: 4.962

6.  Kinetics of interleukin-2 and interleukin-6 synthesis following major mechanical trauma.

Authors:  W Ertel; E Faist; C Nestle; L Hueltner; M Storck; F W Schildberg
Journal:  J Surg Res       Date:  1990-06       Impact factor: 2.192

7.  The release of interleukin-1 beta (IL-1) precedes that of interleukin 6 (IL-6) in patients undergoing major surgery.

Authors:  R J Baigrie; P M Lamont; M Dallman; P J Morris
Journal:  Lymphokine Cytokine Res       Date:  1991-08

8.  Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells.

Authors:  P Ghezzi; C A Dinarello; M Bianchi; M E Rosandich; J E Repine; C W White
Journal:  Cytokine       Date:  1991-05       Impact factor: 3.861

9.  Experimental hemorrhage and blunt trauma do not increase circulating tumor necrosis factor.

Authors:  S Stylianos; G Wakabayashi; J A Gelfand; B H Harris
Journal:  J Trauma       Date:  1991-08

10.  Differential alterations in plasma IL-6 and TNF levels after trauma and hemorrhage.

Authors:  A Ayala; P Wang; Z F Ba; M M Perrin; W Ertel; I H Chaudry
Journal:  Am J Physiol       Date:  1991-01
View more
  138 in total

1.  [Clinical course and prognostic significance of immunological and functional parameters after severe trauma].

Authors:  S Lendemans; E Kreuzfelder; C Waydhas; D Nast-Kolb; S Flohé
Journal:  Unfallchirurg       Date:  2004-03       Impact factor: 1.000

2.  [Protective ventilation in the operating room: absence of evidence is not evidence of absence].

Authors:  M Gama de Abreu; A Güldner; T Koch
Journal:  Anaesthesist       Date:  2010-07       Impact factor: 1.041

3.  Pharmacologic suppression of inflammation by a diphenyldifluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival.

Authors:  Vivek R Yadav; Kaustuv Sahoo; Pamela R Roberts; Vibhudutta Awasthi
Journal:  J Pharmacol Exp Ther       Date:  2013-08-30       Impact factor: 4.030

4.  Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice.

Authors:  Ricky Cheung; Fran Shen; Joseph H Phillips; Mandy J McGeachy; Daniel J Cua; Paul G Heyworth; Robert H Pierce
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

5.  Can local secretion of prostaglandin E2, thromboxane B2, and interleukin-6 play a role in ruptured abdominal aortic aneurysm?

Authors:  Bernice L Y Cheuk; Stephen W K Cheng
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

6.  Inhibition of Fas-Fas ligand interaction attenuates microvascular hyperpermeability following hemorrhagic shock.

Authors:  Devendra A Sawant; Binu Tharakan; Richard P Tobin; Hayden W Stagg; Felicia A Hunter; M Karen Newell; W Roy Smythe; Ed W Childs
Journal:  Shock       Date:  2013-02       Impact factor: 3.454

7.  Hemorrhagic shock augments Nlrp3 inflammasome activation in the lung through impaired pyrin induction.

Authors:  Peng Xu; Zongmei Wen; Xueyin Shi; Yuehua Li; Liyan Fan; Meng Xiang; Aijun Li; Melanie J Scott; Guozhi Xiao; Song Li; Timothy R Billiar; Mark A Wilson; Jie Fan
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

8.  A trauma-like elevation of plasma cytokines in humans in response to treadmill running.

Authors:  K Ostrowski; C Hermann; A Bangash; P Schjerling; J N Nielsen; B K Pedersen
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

Review 9.  A systems-theoretical framework for health and disease: inflammation and preconditioning from an abstract modeling point of view.

Authors:  Eberhard O Voit
Journal:  Math Biosci       Date:  2008-09-27       Impact factor: 2.144

Review 10.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.